Browsing by Author "Retsky, Michael"
Now showing items 1-20 of 23
-
An argument for discovery-driven research: from physicist to cancer researcher
Retsky, Michael W. (Cancer Intelligence, 2014) -
Colonoscopy to Prevent Colon Cancer: It Works but There Seems to be a Quality Issue
Retsky, Michael W. (OMICS International, 2015) -
Comments on John D. Keen and James E. Keen, What is the point: will screening mammography save my life? BMC Medical Informatics and Decision Making, 2009
Retsky, Michael W. (BioMed Central, 2009)This paper by John D. Keen and James E. Keen addresses a thorny subject. The numerical findings and commentaries in their paper will be disturbing to some readers and seem to defy logic and well established viewpoints. It ... -
Computer Model Challenges Breast Cancer Treatment Strategy
Retsky, Michael W.; Swartzendruber, Douglas E.; Bame, Paul D.; Wardwell, Robert H. (Informa UK Limited, 1994)The breast cancer treatment failure rate remains unacceptably high. The current breast cancer treatment paradigm, based primarily on Gompertzian kinetics and animal models, advocates short-course, intensive chemotherapy ... -
Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer
Retsky, Michael W.; Demicheli, R.; Hrushesky, W. J. M.; Baum, M.; Gukas, I. D. (Wiley-Blackwell, 2008)To explain bimodal relapse patterns observed in breast cancer data, we have proposed that metastatic breast cancer growth commonly includes periods of temporary dormancy at both the single cell phase and the avascular ... -
Guest Editor's Concluding Remarks―Advances in Usage of ANN, Discussion of an Unsolved Problem, and Some Differences between Papers Written by Engineers and by Physicians
Retsky, Michael W. (Molecular Diversity Preservation International (MDPI), 2009) -
How Long Should Adjuvant Chemotherapy Be Given in Early Stage Colon Cancer?
Retsky, Michael W. (OMICS Publishing Group, 2013)After diagnosis of colon cancer, the tumor is removed and the stage of the disease is provided by a pathologist. If the stage indicates relatively high risk of relapse, adjuvant chemotherapy is used for 6 or so months to ... -
Hypothesis: Induced Angiogenesis after Surgery in Premenopausal Node-Positive Breast Cancer Patients Is a Major Underlying Reason Why Adjuvant Chemotherapy Works Particularly Well for Those Patients
Retsky, Michael W.; Bonadonna, Gianni; Demicheli, Romano; Folkman, Judah; Hrushesky, William; Valagussa, Pinuccia (BioMed Central, 2004)Background: We suggest that surgical extirpation of primary breast cancer among other effects accelerates relapse for some premenopausal node-positive patients. These accelerated relapses occur within 10 months of surgery ... -
Hypothesis: Primary Antiangiogenic Method Proposed to Treat Early Stage Breast Cancer
Retsky, Michael W.; Hrushesky, William JM; Gukas, Isaac D (BioMed Central, 2009)Background: Women with Down syndrome very rarely develop breast cancer even though they now live to an age when it normally occurs. This may be related to the fact that Down syndrome persons have an additional copy of ... -
Is there a rationale for an anesthesiologist's role against cancer recurrence?
Forget, P; Coulie, P. G.; Retsky, Michael W.; Demicheli, R.; Machiels, J. P.; De Kock, M. (Amb Acta Medica Belgica, 2013)Growth of tumors can accelerate during the peri-operative period. Accordingly, early relapse of cancer occurs in some patients during the first two postoperative years. Temporal and biologic analyses of cancer pathophysiology ... -
Menopausal Status Dependence of the Timing of Breast Cancer Recurrence after Surgical Removal of the Primary Tumour
Demicheli, Romano; Bonadonna, Gianni; Hrushesky, William JM; Retsky, Michael W.; Valagussa, Pinuccia (BioMed Central, 2004)Introduction: Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence. Methods: The hazard rate for local-regional ... -
Metronomic Chemotherapy Was Originally Designed and First Used in 1994 for Early Stage Cancer -- Why Is It Taking So Long to Proceed?
Retsky, Michael W. (OMICS Publishing Group, 2011)This is a personal case history from a researcher who was studying tumor growth when diagnosed in 1994 with stage IIIc colon cancer. The risk of relapse was 80% without therapy and 50% with conventional therapy. However ... -
Multimodal Hazard Rate for Relapse in Breast Cancer: Quality of Data and Calibration of Computer Simulation
Retsky, Michael W.; Demicheli, Romano (MDPI AG, 2014)Much has occurred since our 2010 report in Cancers. In the past few years we published several extensive reviews of our research so a brief review is all that will be provided here. We proposed in the earlier reports that ... -
NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup
Retsky, Michael W.; Rogers, Rick A.; Demicheli, Romano; Hrushesky, William J. M.; Gukas, Isaac; Vaidya, Jayant S.; Baum, Michael; Forget, Patrice; DeKock, Marc; Pachmann, Katharina (Springer, 2012)To explain a bimodal relapse hazard among early stage breast cancer patients treated by mastectomy we postulated that relapses within 4 years of surgery resulted from something that happened at about the time of surgery ... -
Omics Conferences and Breast Cancer in Sub-Saharan Africa
Retsky, Michael W. (OMICS Publishing Group, 2015) -
Perioperative Inflammation as Triggering Origin of Metastasis Development
Retsky, Michael W.; Demicheli, Romano (Springer Nature, 2017)A multimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia. What began as a simple investigation of these anomalous data has taken ... -
Promising development from translational or perhaps anti-translational research in breast cancer
Retsky, Michael W.; Demicheli, Romano; Hrushesky, William JM; Forget, Patrice; De Kock, Marc; Gukas, Isaac; Rogers, Rick A.; Baum, Michael; Pachmann, Katharine; Vaidya, Jayant S (Springer, 2012)Background: A great deal of the public’s money has been spent on cancer research but demonstrable benefits to patients have not been proportionate. We are a group of scientists and physicians who several decades ago were ... -
Protocol For A Randomised, Multicentre, Double Blinded Phase III Study Of Perioperative Ketorolac In Women Of African Descent With Operable Breast Cancer.
Demicheli, Romano; Osaro, Erhabor; Retsky, Michael W.; Patrice, Forget; Jayant, Vaidya; SO., Bello (Jacobs Publishers, 2016)Cancer remains one of the leading causes of morbidity and mortality worldwide. Breast cancer is the most common form of malignancy occurring in women around the world. The aim of this present protocol is to outline the ... -
Recent Translational Research: Computational Studies of Breast Cancer
Retsky, Michael W.; Demicheli, Romano; Hrushesky, William; Speer, John; Swartzendruber, Douglas; Wardwell, Robert (BioMed Central, 2004)The combination of mathematics – queen of sciences – and the general utility of computers has been used to make important inroads into insight-providing breast cancer research and clinical aids. These developments are in ... -
Recurrence Dynamics Does Not Depend on the Recurrence Site
Demicheli, Romano; Biganzoli, Elia; Boracchi, Patrizia; Greco, Marco; Retsky, Michael W. (BioMed Central, 2008)Introduction: The dynamics of breast cancer recurrence and death, indicating a bimodal hazard rate pattern, has been confirmed in various databases. A few explanations have been suggested to help interpret this finding, ...